Chromosome 9 Deletions and Recurrence of Superficial Bladder Cancer: Identification of Four Regions of Prognostic Interest
Overview
Affiliations
In a previous study, loss of heterozygosity (LOH) of 28 chromosome 9 microsatellite markers was assessed on 139 Ta/T1 bladder tumors. LOH at one or more loci was detected in 67 tumors, 62 presenting subchromosomal deletions. One hundred and thirty-three of these patients have now been followed for up to 8 years. The purpose of the present study was to evaluate the potential biological significance of chromosome 9 deletions in superficial bladder tumors at initial diagnosis. High grade was associated with LOH (P=0.004). Large tumors carried more frequently 9p deletions (P=0.022). Female patients had more chromosome 9q LOH than male patients did (P=0.010). Chromosome 9 LOH at all loci was associated with an elevated risk of recurrence but four regions were associated with a particularly high risk of recurrence. Multivariate analysis taking into account grade, stage, size and number of tumors showed that tumors deleted in the regions 9ptr-p22, 9q22.3, 9q33, and 9q34 recurred significantly more rapidly than those without deletions (Recurrence rate ratio=2.32, 2.53, 2.52 and 2.43 respectively). Log-rank statistics comparing Kaplan-Meier survival curves for the same chromosomal regions confirmed the correlation (P=0.0002, 0.010, 0.002 and 0.009 respectively). Only four patients progressed to muscle-invasive disease. They all had extensive deletions on 9q but none had deletions at 9ptr-p22. This study suggests a link between chromosome 9 anomalies and recurrence of superficial bladder cancer.
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.
Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S Nat Commun. 2022; 13(1):1797.
PMID: 35379845 PMC: 8980015. DOI: 10.1038/s41467-022-29397-z.
The Prognostic Role of CDK9 in Bladder Cancer.
Borowczak J, Szczerbowski K, Maniewski M, Zdrenka M, Slupski P, Antosik P Cancers (Basel). 2022; 14(6).
PMID: 35326643 PMC: 8945910. DOI: 10.3390/cancers14061492.
Giudici N, Bonne F, Blarer J, Minoli M, Krentel F, Seiler R Transl Androl Urol. 2021; 10(10):4036-4050.
PMID: 34804846 PMC: 8575564. DOI: 10.21037/tau-20-1472.
VNTR polymorphism in the breakpoint region of ABL1 and susceptibility to bladder cancer.
Kim M, Yang G, Jeong M, Mun J, Lee S, Nam J BMC Med Genomics. 2021; 14(1):121.
PMID: 33952249 PMC: 8097952. DOI: 10.1186/s12920-021-00968-1.
Mao X, Li B, Liang Y, Li S, Zhou J, He Q Oncol Lett. 2018; 15(5):6533-6540.
PMID: 29731855 PMC: 5920842. DOI: 10.3892/ol.2018.8137.